keyword
MENU ▼
Read by QxMD icon Read
search

Clinical omics

keyword
https://www.readbyqxmd.com/read/29778458/noninvasive-diagnosis-of-endometriosis-review-of-current-peripheral-blood-and-endometrial-biomarkers
#1
REVIEW
Dorien F O, Idhaliz Flores, Etienne Waelkens, Thomas D'Hooghe
A noninvasive biomarker-based test could help shorten the diagnostic delay for endometriosis. The most investigated biomarker sources are peripheral blood and endometrium. Discovery of endometriosis biomarkers is often hypothesis-driven, i.e. when one or a few biomarkers are investigated based on their role in the disease pathogenesis. Alternatively, a hypothesis-generating approach has been followed using the "omics" technologies. A variety of biomarkers for endometriosis have been investigated, but no biomarker has been validated for clinical use...
April 13, 2018: Best Practice & Research. Clinical Obstetrics & Gynaecology
https://www.readbyqxmd.com/read/29776627/introduction-molecular-medicine-in-the-common-era-applications-and-impact-of-molecular-pathology-in-health-and-disease
#2
REVIEW
Martin H Bluth
The unprecedented expansion of molecular pathology continues to affect and influence the clinical laboratory. Technological advances in high-throughput automation, cost containment, and refined methodology have improved the understanding of pathobiology through application of molecular pathology to multiple disease spaces. Incorporation of this field to emerging omics platforms, pharmacovigilance and biomarker discovery, and accessibility by lay consumers demonstrates the widespread reach of molecular pathology in the clinical marketplace...
June 2018: Clinics in Laboratory Medicine
https://www.readbyqxmd.com/read/29775779/metabolomics-in-breast-cancer-a-decade-in-review
#3
REVIEW
Amelia McCartney, Alessia Vignoli, Laura Biganzoli, Richard Love, Leonardo Tenori, Claudio Luchinat, Angelo Di Leo
Breast cancer (BC) is a heterogeneous disease which has been characterised and stratified by many platforms such as clinicopathological risk factors, genomic assays, computer generated models, and various "-omic" technologies. Genomic, proteomic and transcriptomic analysis in breast cancer research is well established, and metabolomics, which can be considered a downstream manifestation of the former disciplines, is of growing interest. The past decade has seen significant progress made within the field of clinical metabolomic BC research, with several groups demonstrating results with significant promise in the setting of BC screening and biological characterisation, as well as future potential for prognostic metabolomic biomarkers...
May 3, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29761474/lipids-apolipoproteins-and-inflammatory-biomarkers-of-cv-risk-what-have-we-learned
#4
David Rhainds, Mathieu R Brodeur, Jean-Claude Tardif
Cardiovascular diseases (CVD) are the first cause of death in the world. CVD risk is influenced by multiple factors, some non-modifiable such as age, sex and genetic background, and others modifiable. Great progress has been made over the last decades in the identification of biomarkers of incident or recurrent CV risk and surrogate endpoints of CV outcomes. We present the current state of knowledge for CV biomarkers in plasma including lipids, apolipoproteins, inflammation-related, and emerging omics-based biomarkers...
May 15, 2018: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29752463/personalization-of-prostate-cancer-therapy-through-phosphoproteomics
#5
REVIEW
Wei Yang, Michael R Freeman, Natasha Kyprianou
Castration-resistant prostate cancer (CRPC) remains incurable despite the approval of several new treatments. Identification of new biomarkers and therapeutic targets to enable personalization of CRPC therapy, with the aim of maximizing therapeutic responses and minimizing toxicity in patients, is urgently needed. Prostate cancer progression and therapeutic resistance are frequently driven by aberrantly activated kinase signalling pathways that are amenable to pharmacological inhibition. Personalized phosphoproteomics, which enables the analysis of signalling networks in individual tumours, is a promising approach to advance personalized therapy by discovering biomarkers of pathway activity and clinically actionable targets...
May 11, 2018: Nature Reviews. Urology
https://www.readbyqxmd.com/read/29752036/blood-biomarkers-in-alzheimer-s-disease
#6
M Altuna-Azkargorta, M Mendioroz-Iriarte
INTRODUCTION: The early diagnosis of Alzheimer's disease (AD) via the use of biomarkers could facilitate the implementation and monitoring of early therapeutic interventions with the potential capacity to significantly modify the course of the disease. DEVELOPMENT: Classic cerebrospinal fluid biomarkers and approved structural and functional neuroimaging have a limited clinical application given their invasive nature and/or high cost. The identification of more accessible and less costly biomarkers, such as blood biomarkers, would facilitate application in clinical practice...
May 8, 2018: Neurología: Publicación Oficial de la Sociedad Española de Neurología
https://www.readbyqxmd.com/read/29746147/female-sex-and-gender-in-lung-sleep-health-and-disease-increased-understanding-of-basic-biological-pathophysiological-and-behavioral-mechanisms-leading-to-better-health-for-female-patients-with-lung-disease
#7
MeiLan K Han, Emilio Arteaga-Solis, John Blenis, Ghada Bourjeily, Deborah J Clegg, Dawn DeMeo, Jeanne Duffy, Ben Gaston, Nicola M Heller, Anna Hemnes, Elizabeth Petri Henske, Raksha Jain, Tim Lahm, Lisa H Lancaster, Joyce Lee, Marianne J Legato, Sherry McKee, Reena Mehra, Alison Morris, Y S Prakash, Martin R Stampfli, Rashmi Gopal-Srivastava, Aaron D Laposky, Antonello Punturieri, Lora Reineck, Xenia Tigno, Janine Clayton
Female sex/gender is an under-characterized variable in studies related to lung development and disease. Notwithstanding, many aspects of lung and sleep biology and pathobiology are impacted by female sex and female reproductive transitions. These may manifest as differential gene expression or peculiar organ development. Some conditions are more prevalent in women, such as asthma and insomnia, or in the case of LAM, are seen almost exclusively in women. In other diseases, presentation differs such as the higher frequency of exacerbations experienced by women with COPD or greater cardiac morbidity among women with sleep disordered breathing...
May 10, 2018: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/29743935/pharmacokinetics-of-chinese-medicines-strategies-and-perspectives
#8
REVIEW
Ru Yan, Ying Yang, Yijia Chen
The modernization and internationalization of Chinese medicines (CMs) are hampered by increasing concerns on the safety and the efficacy. Pharmacokinetic (PK) study is indispensable to establish concentration-activity/toxicity relationship and facilitate target identification and new drug discovery from CMs. To cope with tremendous challenges rooted from chemical complexity of CMs, the classic PK strategies have evolved rapidly from PK study focusing on marker/main drug components to PK-PD correlation study adopting metabolomics approaches to characterize associations between disposition of global drug-related components and host metabolic network shifts...
2018: Chinese Medicine
https://www.readbyqxmd.com/read/29743053/pdxliver-a-database-of-liver-cancer-patient-derived-xenograft-mouse-models
#9
Sheng He, Bo Hu, Chao Li, Ping Lin, Wei-Guo Tang, Yun-Fan Sun, Fang-You-Min Feng, Wei Guo, Jia Li, Yang Xu, Qian-Lan Yao, Xin Zhang, Shuang-Jian Qiu, Jian Zhou, Jia Fan, Yi-Xue Li, Hong Li, Xin-Rong Yang
BACKGROUND: Liver cancer is the second leading cause of cancer-related deaths and characterized by heterogeneity and drug resistance. Patient-derived xenograft (PDX) models have been widely used in cancer research because they reproduce the characteristics of original tumors. However, the current studies of liver cancer PDX mice are scattered and the number of available PDX models are too small to represent the heterogeneity of liver cancer patients. To improve this situation and to complement available PDX models related resources, here we constructed a comprehensive database, PDXliver, to integrate and analyze liver cancer PDX models...
May 9, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29734647/recent-advances-in-prostate-cancer-treatment-and-drug-discovery
#10
REVIEW
Ekaterina Nevedomskaya, Simon J Baumgart, Bernard Haendler
Novel drugs, drug sequences and combinations have improved the outcome of prostate cancer in recent years. The latest approvals include abiraterone acetate, enzalutamide and apalutamide which target androgen receptor (AR) signaling, radium-223 dichloride for reduction of bone metastases, sipuleucel-T immunotherapy and taxane-based chemotherapy. Adding abiraterone acetate to androgen deprivation therapy (ADT) in order to achieve complete androgen blockade has proven highly beneficial for treatment of locally advanced prostate cancer and metastatic hormone-sensitive prostate cancer (mHSPC)...
May 4, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29733683/biobanking-in-a-challenging-african-environment-unique-experience-from-the-siren-project
#11
Rufus O Akinyemi, Kazeem Akinwande, Samuel Diala, Osi Adeleye, Abiodun Ajose, Kehinde Issa, Dorcas Owusu, Isaac Boamah, Isah Suleiman Yahaya, Abdulraheem Olayemi Jimoh, Lucius Imoh, Gregory Fakunle, Albert Akpalu, Fred Sarfo, Kolawole Wahab, Emmanuel Sanya, Lukman Owolabi, Reginald Obiako, Godwin Osaigbovo, Morenikeji Komolafe, Michael Fawale, Philip Adebayo, Paul Olowoyo, Yahaya Obiabo, Taofiki Sunmonu, Ijezie Chukwuonye, Olayemi Balogun, Basirat Adeoye, Florence Oladele, Peter Olowoniyi, Frederick Adeyemi, Arthur Lezzi, Ajibola Tunde Falayi, Michael Fasanya, Kolawole Ogunwale, Olabisi Adeola, Omolara Olomu, Olumayowa Aridegbe, Ruth Laryea, Ezinne Uvere, Moyinoluwalogo Faniyan, Ezinne Melikam, Raelle Tagge, Onoja Akpa, Joshua Akinyemi, Oyedunni Arulogun, Hemant K Tiwari, Bruce Ovbiagele, Mayowa Owolabi
Africa was previously insufficiently represented in the emerging discipline of biobanking despite commendable early efforts. However, with the Human, Heredity, and Health in Africa (H3Africa) initiative, biorepository science has been bolstered, regional biobanks are springing up, and awareness about biobanks is growing on the continent. The Stroke Investigative Research and Educational Network (SIREN) project is a transnational, multicenter, hospital and community-based study involving over 3000 cases and 3000 controls recruited from 16 sites in Ghana and Nigeria...
May 7, 2018: Biopreservation and Biobanking
https://www.readbyqxmd.com/read/29731454/-diagnosis-and-treatment-of-rheumatoid-arthritis-toward-the-best-practice-statistical-genetics-and-rheumatoid-arthritis
#12
Yukinori Okada
Statistical genetics is a research field that assessed causality of human genome variations on phenotypes. Recent development of genome sequencing technologies provided abundant lists of causal genome variations associated with human clinical phenotypes. Integration of disease genome information with a variety of epigenetics by trans-layer omics analysis elucidated cell type specificity of the diseases, disease biology, and genome-based novel drug discovery.
2018: Clinical Calcium
https://www.readbyqxmd.com/read/29728051/ensemble-outlier-detection-and-gene-selection-in-triple-negative-breast-cancer-data
#13
Marta B Lopes, André Veríssimo, Eunice Carrasquinha, Sandra Casimiro, Niko Beerenwinkel, Susana Vinga
BACKGROUND: Learning accurate models from 'omics data is bringing many challenges due to their inherent high-dimensionality, e.g. the number of gene expression variables, and comparatively lower sample sizes, which leads to ill-posed inverse problems. Furthermore, the presence of outliers, either experimental errors or interesting abnormal clinical cases, may severely hamper a correct classification of patients and the identification of reliable biomarkers for a particular disease. We propose to address this problem through an ensemble classification setting based on distinct feature selection and modeling strategies, including logistic regression with elastic net regularization, Sparse Partial Least Squares - Discriminant Analysis (SPLS-DA) and Sparse Generalized PLS (SGPLS), coupled with an evaluation of the individuals' outlierness based on the Cook's distance...
May 4, 2018: BMC Bioinformatics
https://www.readbyqxmd.com/read/29726581/pregomics-leveraging-systems-biology-and-bioinformatics-for-drug-repurposing-in-maternal-child-health
#14
Jeffery A Goldstein, Lisa A Bastarache, Joshua C Denny, Jill M Pulley, David M Aronoff
Obstetric diseases remain underserved and understudied. Drug repurposing-utilization of a drug whose use is accepted in one condition for a different condition-could represent a rapid and low-cost way to identify new therapies that are known to be safe. In diseases of pregnancy, the known safety profile is a strong additional incentive. We describe the techniques and steps used in the use of 'omics data for drug repurposing. We illustrate these techniques using case studies of published drug repurposing projects...
May 4, 2018: American Journal of Reproductive Immunology: AJRI
https://www.readbyqxmd.com/read/29724001/unraveling-nutritional-regulation-of-tacrolimus-biosynthesis-in-streptomyces-tsukubaensis-through-omic-approaches
#15
REVIEW
María Ordóñez-Robles, Fernando Santos-Beneit, Juan F Martín
Streptomyces tsukubaensis stands out among actinomycetes by its ability to produce the immunosuppressant tacrolimus. Discovered about 30 years ago, this macrolide is widely used as immunosuppressant in current clinics. Other potential applications for the treatment of cancer and as neuroprotective agent have been proposed in the last years. In this review we introduce the discovery of S. tsukubaensis and tacrolimus, its biosynthetic pathway and gene cluster ( fkb ) regulation. We have focused this work on the omic studies performed in this species in order to understand tacrolimus production...
May 1, 2018: Antibiotics
https://www.readbyqxmd.com/read/29723191/role-of-duplicate-genes-in-determining-the-tissue-selectivity-of-hereditary-diseases
#16
Ruth Barshir, Idan Hekselman, Netta Shemesh, Moran Sharon, Lena Novack, Esti Yeger-Lotem
A longstanding puzzle in human genetics is what limits the clinical manifestation of hundreds of hereditary diseases to certain tissues, while their causal genes are expressed throughout the human body. A general conception is that tissue-selective disease phenotypes emerge when masking factors operate in unaffected tissues, but are specifically absent or insufficient in disease-manifesting tissues. Although this conception has critical impact on the understanding of disease manifestation, it was never challenged in a systematic manner across a variety of hereditary diseases and affected tissues...
May 3, 2018: PLoS Genetics
https://www.readbyqxmd.com/read/29721916/integration-of-genomics-and-metabolomics-for-prioritization-of-rare-disease-variants-a-2018-literature-review
#17
Emma Graham, Jessica Lee, Magda Price, Maja Tarailo-Graovac, Allison Matthews, Udo Engelke, Jeffrey Tang, Leo A J Kluijtmans, Ron A Wevers, Wyeth W Wasserman, Clara D M van Karnebeek, Sara Mostafavi
Many inborn errors of metabolism (IEMs) are amenable to treatment; therefore, early diagnosis and treatment is imperative. Despite recent advances, the genetic basis of many metabolic phenotypes remains unknown. For discovery purposes, whole exome sequencing (WES) variant prioritization coupled with clinical and bioinformatics expertise is the primary method used to identify novel disease-causing variants; however, causation is often difficult to establish due to the number of plausible variants. Integrated analysis of untargeted metabolomics (UM) and WES or whole genome sequencing (WGS) data is a promising systematic approach for identifying disease-causing variants...
May 2, 2018: Journal of Inherited Metabolic Disease
https://www.readbyqxmd.com/read/29720575/prediction-of-acute-gvhd-and-relapse-by-metabolic-biomarkers-after-allogeneic-hematopoietic-stem-cell-transplantation
#18
Xiaojin Wu, Yiyu Xie, Chang Wang, Yue Han, Xiebing Bao, Shoubao Ma, Ahmet Yilmaz, Bingyu Yang, Yuhan Ji, Jinge Xu, Hong Liu, Suning Chen, Jianying Zhang, Jianhua Yu, Depei Wu
BACKGROUND: There are very few studies investigating metabolic biomarkers to predict acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Metabolic models can provide a framework for analyzing the information-rich omics data sets in this setting. METHODS: Four hundred and fifty-six samples from one hundred and fourteen consecutive patients who underwent HSCT from January 2012 to May 2014 were collected for this study...
May 3, 2018: JCI Insight
https://www.readbyqxmd.com/read/29720263/early-passaging-of-mesenchymal-stem-cells-does-not-instigate-significant-modifications-in-their-immunological-behavior
#19
Niketa Sareen, Glen Lester Sequiera, Rakesh Chaudhary, Ejlal Abu-El-Rub, Subir Roy Chowdhury, Vikram Sharma, Arun Surendran, Meenal Moudgil, Paul Fernyhough, Amir Ravandi, Sanjiv Dhingra
BACKGROUND: Bone marrow-derived allogeneic mesenchymal stem cells (MSCs) from young healthy donors are immunoprivileged and their clinical application for regenerative medicine is under evaluation. However, data from preclinical and initial clinical trials indicate that allogeneic MSCs after transplantation provoke a host immune response and are rejected. In the current study, we evaluated the effect of an increase in passage number in cell culture on immunoprivilege of the MSCs. Since only limited numbers of MSCs can be sourced at a time from a donor, it is imperative to expand them in culture to meet the necessary numbers required for cell therapy...
May 2, 2018: Stem Cell Research & Therapy
https://www.readbyqxmd.com/read/29715491/recent-updates-and-challenges-on-the-regulation-of-precision-medicine-the-united-states-in-perspective
#20
Lin-Chau Chang, Thomas E Colonna
The rapid progress in "omics", such as genomics, metabolomics, microbiomics, has paved the path for precision medicine and revolutionized the development of drugs and devices promising to meet unmet medical needs. The aim of the present study was to investigate the current regulatory framework established by the United States Food and Drug Administration (USFDA) and to identify challenges and concerns through study of related literatures in the PubMed database. We found that efforts were made to facilitate the implementation of precision medicine through organizational reform, publication of guidance documents, and continuous post-market surveillance...
April 28, 2018: Regulatory Toxicology and Pharmacology: RTP
keyword
keyword
29664
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"